StockNews.AI
XCUR
StockNews.AI
9 hrs

Exicure, Inc. Reports Third Quarter 2025 Financial Results

1. XCUR's cash dropped to $4.4 million from $12.5 million. 2. R&D expenses increased to $0.9 million due to GPCR USA acquisition. 3. Net loss rose to $2.4 million, primarily from higher operating costs. 4. Company's cash is insufficient for operations; need for substantial financing. 5. Exploring strategic alternatives to maximize stockholder value amid restructuring.

10m saved
Insight
Article

FAQ

Why Bearish?

The significant cash decrease and net loss raise concerns about XCUR's financial health. Historically, companies facing similar cash flow issues have struggled with stock performance.

How important is it?

The article highlights critical financial struggles and the necessity for financing, which could significantly sway investor sentiment.

Why Short Term?

XCUR's immediate need for financing could affect stock prices soon. Short-term financial instability can lead to adverse market reactions, as seen with other biotech firms in need of quick capital.

Related Companies

GPCRBCRXSYN
November 07, 2025 16:00 ET  | Source: Exicure, Inc. REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. (“GPCR USA”), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses. General and Administrative (G&A) Expense: General and administrative expenses were $1.5 million for the quarter ended September 30, 2025, as compared to $1.4 million for the quarter ended September 30, 2024. The increase in G&A expense of $0.1 million for the three months ended September 30, 2025 was mostly due to the additional expenses incurred from the acquisition of GPCR USA. Loss from sale or disposal of property and equipment: The Company recognized a $4,000 loss from GPCR USA’s sale of fixed assets. Other Income and Expense: The Company recognized a loss of $246,000 related to the change in the fair value of its contingent liability. The Company satisfied its self-insured retainer with the insurer during the third quarter of 2025 resulting in a gain of $155,000. Net Loss: The Company had a net loss of $2.4 million for the quarter ended September 30, 2025, as compared to a net loss of $1.1 million for the quarter ended September 30, 2024. The increase in net loss of $1.3 million was primarily due to the increased operating expenses from the acquisition of GPCR USA. Going Concern: Management believes that the Company’s existing cash and cash equivalents is not sufficient to continue to fund operations. The Company has already engaged in significant cost reductions, and our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. The Company also needs to raise capital to fund its operations. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms. About Exicure, Inc. Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company’s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value, the timing of the equity investment closing and potential additional equity investment and the Nasdaq Hearings Panel process and potential results. Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “advance,” “believes,” “target,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 18, 2025, as updated by the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law. Media Contact:Sarah Ellinwood, PhDKendall Investor Relationssellinwood@kendallir.com  EXICURE, INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)  September 30,2025 December 31,2024    ASSETS   Current assets:   Cash and cash equivalents$4,438  $12,508 Other receivable 55   521 Prepaid expenses and other current assets 946   644 Total current assets 5,439   13,673 Other noncurrent assets 1,888   1,357 Property and equipment, net 527   26 Right-of-use asset, net 289   — Intangible asset 3,784   — Goodwill 3,340   — Total assets$15,267  $15,056 LIABILITIES AND STOCKHOLDERS’ EQUITY   Current liabilities:   Accounts payable$1,307  $1,031 Accrued expenses and other current liabilities 1,462   2,040 Total current liabilities 2,769   3,071 Deferred revenue, noncurrent 26   — Lease liability, noncurrent —   5,213 Contingent consideration 5,545   — Total liabilities 8,340   8,284     Commitments and Contingencies (Note 12)       Stockholders’ equity:   Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, September 30, 2025 and December 31, 2024 —   — Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 6,373,869 issued and outstanding, September 30, 2025; 6,026,841 issued and outstanding, December 31, 2024 1   1 Additional paid-in capital 208,136   206,035 Accumulated other comprehensive income 102   — Accumulated deficit (201,312)  (199,264)Total stockholders' equity 6,927   6,772 Total liabilities and stockholders’ equity$15,267  $15,056       EXICURE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share data)  Three Months EndedSeptember 30, Nine Months EndedSeptember 30,  2025   2024   2025   2024 Revenue:       Revenue$—  $—  $—  $500 Total revenue —   —   —   500 Operating expenses:       Research and development expense 888   —   2,631   — General and administrative expense 1,499   1,434   5,230   4,005 Litigation legal expense —   1,138   —   1,138 Loss from sale or disposal of property and equipment 4   —   90   — Gain on early lease termination —   —   (5,974)  — Total operating expenses 2,391   2,572   1,977   5,143 Operating loss (2,391)  (2,572)  (1,977)  (4,643)Other income (expense), net:       Dividend income 27   —   106   5 Interest income 29   1   38   7 Interest expense —   (12)  —   (18)Gain on settlement of accounts payables 155   —   346   — Change in fair value of contingent liability (246)  —   (541)  — Other (expense) income, net (11)  1,500   (20)  2,137 Total other (expense) income, net (46)  1,489   (71)  2,131 Net loss before provision for income taxes (2,437)  (1,083)  (2,048)  (2,512)Provision for income taxes —   (8)  —   (8)Net loss$(2,437) $(1,091) $(2,048) $(2,520)        Basic and diluted loss per common share$(0.39) $(0.57) $(0.33) $(1.36)        Weighted-average basic and diluted common shares outstanding 6,322,078   1,899,412   6,271,229   1,855,286 

Related News